vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average – Time to Sell?

vTv Therapeutics Inc. (NASDAQ:VTVT) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $14.63 and traded as low as $13.75. vTv Therapeutics shares last traded at $13.75, with a volume of 2,997 shares trading hands.

vTv Therapeutics Trading Down 6.8 %

The firm’s 50-day moving average is $14.63 and its 200-day moving average is $18.91. The firm has a market cap of $41.39 million, a price-to-earnings ratio of -1.56 and a beta of 0.63.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter.

Institutional Trading of vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. Baker BROS. Advisors LP bought a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 97,314 shares of the biotechnology company’s stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned about 3.23% of vTv Therapeutics as of its most recent SEC filing. 17.51% of the stock is owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.